| 1/3 | US=22 / Urologia George S, Bukowski RM. Sorafenib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 167-87. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; SORAFENIB; INIBIDOR DE TIROSINA CINASE; VEGF; TERAPIA ANTIANGIOGENICA |
| 2/3 | US=50 / Câncer Ryan CJ. Development in the management of genitourinary malignancies: prostate cancer and renal cell carcinoma. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 533-44. ISBN 978-1-60327-086-1. DOENCAS MALIGNAS DO APARELHO GENITURINARIO; CANCER DE PROSTATA; CARCINOMA DE CELULAS RENAIS; CASTRACAO-RESISTENTE O CANCER DE PROSTATA; ANDROGENIOS ADRENAIS; IMUNOTERAPIA; FASE II; ABIRATERONA; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; QUIMIOTERAPIA; GVAX; IPILIMUMAB; IXABEPILONA; SATRAPLATIN; SIPULEUCEL-T; VEGF; SUNITINIB; SORAFENIB |
| 3/3 | US=50 / Câncer Hauschild A, Kahler KC, Egberts F. Sorafenib, a multikinase inhibitor: results from clinical trials in melanoma patients. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 565-74. ISBN 978-1-60327-086-1. SORAFENIB. INIBIDOR MULTIQUINASE; PACIENTES COM MELANOMA; MELANOMA; METASTASE; SORAFENIB; INIBIDORES MULTIQUINASE |